Pharmacological Targets in Metabolic Diseases

Marcos Roberto de Oliveira, PhD earned his bachelor’s degree in Biological Sciences at Federal University of Rio Grande do Sul (UFRGS) in 2005, followed by a master’s and a Ph.D. in Biochemistry from the same institution. He is currently a professor and coordinates research at UFRGS. His research focuses on the neuroprotection mediated by natural molecules and involves studies on mitochondrial physiology, redox biology, bioenergetics, and inflammation in both in vitro and in vivo experimental models.

• Part I: Subsection: Overview of metabolic diseases and disorders, biological alterations, and pharmacological targetsSection I: Molecular level1. Molecular and cellular targets in the management of metabolic diseases and disorders: an overview2. Pharmaceutical aspects of conventional and recent developments for the treatment of metabolic diseases and disorders3. NADPH oxidase, obesity and metabolic syndrome: therapeutic opportunity4. Targeting reactive carbonyls in metabolic disordersSection II: Subcellular and cellular levels5. Targeting autophagy in metabolic diseases6. Endoplasmic reticulum as a pharmacological target in metabolic diseases7. Pharmacologically targeting caveolae in metabolic diseasesPart II: Subsection: Organs as pharmacological targets in metabolic diseases and disorders8. The gut-brain axis as a pharmacological target for depressive disorder and Alzheimer’s disease in diabetes {i|mellitus}9. Cardiomyopathy in metabolic diseases: pharmacological strategies10. Diabetic kidney disease: treatment and challenges11. Unraveling the Enigma of Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Therapeutic Horizons12. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosisPart III: Subsection: Obesity13. Pharmacological targets in obesity14. Adipose tissue and metabolic diseases: a target for prevention and treatment of metabolic diseasesPart IV: Subsection: Metabolic syndrome15. Metabolic syndrome: pharmacological strategies and challenges16. Pharmacological targets in metabolic syndrome-related dyslipidemia17. Plant molecules and metabolic syndrome: therapeutic opportunitiesPart V: Subsection: Natural molecules and metabolic diseases and disorders18. Polyphenols and obesity: molecular targets and therapeutic potential19. Plant Molecules: Prevention and Management of Diabetes Mellitus20. Molecular targets in dyslipidemia: therapeutic potential of plant molecules21. Polyphenols and the control of immunometabolism as a pharmacological targetPart VI: Subsection: Microbiota and metabolic diseases and disorders22. Microbiota, metabolic disorders and pharmacological opportunities23. Gut microbiota as a pharmacological target in cardiovascular diseases24. Plant molecules in obesity and the gut microbiota25. Microbiota and fatty liver disease: potential candidate for therapeutic interventionPart VII: Subsection: Nutrition and food interactions26. Nutrition and Drug Interactions in Metabolic Diseases